For years, a quiet fear has shadowed pregnant women who depend on antidepressants: the worry that the medication keeping them stable might somehow alter the developing mind of their child. A landmark meta-analysis published in The Lancet Psychiatry, drawing on data from more than 600,000 medicated pregnancies, now offers what science rarely delivers so cleanly — reassurance grounded in scale. When researchers separated the effect of the drugs from the genetic and psychiatric inheritance of the parents themselves, the suspected link to autism and ADHD dissolved, suggesting that untreated matern
El Nacional
· May 15, 2026
· health
· 2 min de lectura
High
Verificación: Verificado
Major study finds no causal link between pregnancy antidepressants and autism
◉
Technology
2547 artículos relacionados
Usuarios de PayPal pueden obtener un año gratis de Perplexity Pro
LA RAZÓN · 99% coincidencia
Los 'Siete Magníficos' asiáticos: TSMC, Samsung y compañía dominan mer…
Expansión · 99% coincidencia
Anthropic presenta Claude Opus 4.7 con mejoras sustanciales en ingenie…
Digital Trends Español · 99% coincidencia
¿Sobrevivirá el teléfono inteligente a la era de la inteligencia artif…
Diario Gestión · 99% coincidencia
MANGOS: el nuevo acrónimo de Wall Street que arrasa en la inversión en…
El Economista · 99% coincidencia
Cobertura Relacionada
Idealista · Aug 21
Mark Zuckerberg compra un histórico castillo neogótico del siglo XIX en Irlanda
Mark Zuckerberg y su esposa compraron Strancally Castle, una propiedad neogótica de 1830 en Waterford, Irlanda, valorada…
Cadena SER · Aug 21 Las gafas inteligentes de Meta se prohíben en Reino Unido por preocupaciones de privacidadLas gafas inteligentes de Meta están siendo prohibidas en tribunales, pubs y teatros del Reino Unido por preocupaciones …
Infobae · Aug 21 GIGABYTE AORUS lanza en Argentina su notebook gamer más potente con Ryzen 9 y RTX 5090GIGABYTE AORUS presenta en Argentina la AORUS MASTER 16 (Gen 2), una notebook gamer de gama alta equipada con procesador…
EL UNIVERSAL · Aug 21 Apple Maps despliega caminantes con cámaras 360° para cartografiar zonas inaccesiblesApple financia a personas equipadas con cámaras de 360 grados y GPS para cartografiar áreas inaccesibles a vehículos, me…
Sesgo y Encuadre
⚖
Article presents reassuring findings from a large meta-analysis with minimal bias, though it could better acknowledge remaining uncertainties and alternative explanations.
Bias Direction
center
Confidence
MED
Scientific authority framing - relies heavily on study credibility and expert consensus to present reassuring conclusions about antidepressant safety during pregnancy
pruebas tranquilizadoras (reassuring evidence)
mejor evidencia (best evidence)
descarta vinculo causal (rules out causal link)
Perspectives from pregnant women or patient advocacy groups regarding medication decisions
Discussion of limitations or caveats in meta-analysis methodology
Alternative viewpoints from researchers who found associations in previous studies
Perspectives on the complexity of disentangling medication effects from underlying maternal mental health conditions
Information about ongoing monitoring or post-market surveillance
Impacto Geopolítico
🌎
Medical research finding on antidepressant safety has no geopolitical implications; this is a public health matter without international power dynamics.
Escalation Risk
low
Confidence
HIGH
Lente Económico
📈
Meta-analysis of 600,000+ pregnancies finds no causal link between common antidepressants and autism/ADHD, reducing medical liability concerns and supporting continued psychiatric treatment during pregnancy.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical/Antidepressant Manufacturing
Healthcare/Mental Health Services
Insurance/Medical Liability
Obstetrics and Gynecology
Psychiatric Care
Pregnant women with depression/anxiety can continue antidepressant treatment with greater confidence, reducing treatment discontinuation and associated maternal health risks; reduces parental anxiety about medication safety and potential out-of-pocket costs for alternative treatments.
Likely to strengthen clinical guidelines recommending antidepressant continuation during pregnancy; may reduce litigation risk for pharmaceutical companies and healthcare providers; could influence insurance coverage policies to maintain antidepressant access for pregnant patients; potential regulatory clarification of pregnancy safety labeling.